Stuart Holden Acquires 20,000 Shares of URGN
Stuart Holden purchased 20,000 shares of URGN on June 22, 2026.
Key Points
- Stuart Holden bought 20,000 shares of URGN on June 22, 2026, at an undisclosed price.
- URGN shares traded near $35.80 on Wednesday, amidst insider buying activity.
- Analysts from HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating on URGN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stuart Holden made a significant move by purchasing 20,000 shares of URGN on June 22, 2026. The transaction was not part of a pre-planned trading scheme, but the price at which the shares were acquired wasn't disclosed.
Other Institutional Activity in URGN
RTW Investments, LP maintained its position in URGN with 4,543,895 shares valued at about $81.7 million. BlackRock, Inc. increased its stake by 244,558 shares, ending with 2,845,567 shares worth roughly $51.2 million, marking a 9.4% increase. Toronto Dominion Bank and Kynam Capital Management, LP both opened new positions, holding 2,616,714 and 2,247,393 shares valued at approximately $47.0 million and $40.4 million, respectively. Morgan Stanley slightly trimmed its holdings by 2,863 shares to 2,560,038 shares, valued at around $46.0 million.
UroGen Pharma Ltd. Stock Down 17.9%
Shares of URGN traded near $35.80 on Wednesday. The stock has been a focus for investors, with several institutional activities reflecting varied interests in the company.
$URGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders at URGN made notable purchases. Robinson James Jr. bought 8,000 and 10,000 shares in two separate transactions. Leana Wen acquired 10,000 shares, while Arie Belldegrun purchased 20,000 shares. Additionally, Cynthia Butitta and Daniel George Wildman each bought 10,000 shares. None of these transactions were part of a pre-planned trading plan.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained its 'buy' rating for URGN, setting a price target of $45. Oppenheimer also maintained a 'buy' rating on May 7, 2026, with a target of $40. The consensus among analysts remains positive, with a strong buy recommendation.
About URGN
URGN is a biopharmaceutical company focused on developing and commercializing novel therapies to treat urothelial and specialty cancers. The company aims to address unmet medical needs, offering innovative solutions for patients worldwide.
Bottom Line
Stuart Holden's recent purchase of 20,000 shares of URGN signals confidence in the company's future. The stock's trading activity and insider transactions suggest a keen interest among investors. As always, remember that insider activity and analyst ratings are just part of the broader picture in evaluating a company's potential.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.